NLRP3 INFLAMMASOME ACTIVATION IN MACROPHAGE (RAW 264.7) CELLS BY LIPOPOLISACCARIDE/NIGERICIN: REGULATORY EFFECT OF PSORALIDIN

Damla Setenci; Merve Nur Sultan Yıldırım; Ahmet Cumaoğlu

Makale detayları

NLRP3 INFLAMMASOME ACTIVATION IN MACROPHAGE (RAW 264.7) CELLS BY LIPOPOLISACCARIDE/NIGERICIN: REGULATORY EFFECT OF PSORALIDIN

Yazarlar:

Damla Setenci | Merve Nur Sultan Yıldırım | Ahmet Cumaoğlu

Yayıncı:

Erciyes University

Ana Başlıklar:

Eczacılık ve İlaç Bilimleri

Dergi:

Sağlık Bilimleri Dergisi Vol.32 Issue 3, pp.346-350

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001303654

pISSN:

1018-3655

Anahtar kelimeler:

Özet:

 Psoralidin, a prenylated coumestan, has been reported its anti-inflammatory effect, but the regulatory effects on inflammasome activation and pyroptosis-related cytokines are not clear. The aim of this study was to investigate the regulatory role of psoralidin on inflammasome activation and expression of pyroptosis-related cytokines in Lipopolysaccharide LPSNigericin-stimulated RAW 264.7 macrophages. Regulatory mechanism of psoralidin on inflammasome activation was evaluated using Western blotting for NLRP3, adaptor protein apoptosis-associated speckle-like protein ASCand Caspase-1. Pyroptosis-related cytokines were evaluated using RT-PCR for interleukin-1β IL-1βand interleukin-18 IL18.Non-cytotoxic concentration of Psoralidin 5.0µM significantly inhibited LPSNigericin induced inflamasome activation. In addition, pretreatment with psoralidin suppressed the LPSNigericin-induced production of IL-1β and IL18. Our results indicate that the regulatory effects of psoralidin on inflammasome activation and pyroptosis related cytokine production in RAW 264.7 macrophages are associated with suppression of NLRP3inflammasome activation and inhibition of the release of pyroptosis related cytokines.According to these results, Psoralidine may be considered as a potential therapeutic candidate for the prevention of inflammatory diseases or to support the treatment of inflammation.

 Psoralidin, a prenylated coumestan, has been reported its anti-inflammatory effect, but the regulatory effects on inflammasome activation and pyroptosis-related cytokines are not clear. The aim of this study was to investigate the regulatory role of psoralidin on inflammasome activation and expression of pyroptosis-related cytokines in Lipopolysaccharide LPSNigericin-stimulated RAW 264.7 macrophages. Regulatory mechanism of psoralidin on inflammasome activation was evaluated using Western blotting for NLRP3, adaptor protein apoptosis-associated speckle-like protein ASCand Caspase-1. Pyroptosis-related cytokines were evaluated using RT-PCR for interleukin-1β IL-1βand interleukin-18 IL18.Non-cytotoxic concentration of Psoralidin 5.0µM significantly inhibited LPSNigericin induced inflamasome activation. In addition, pretreatment with psoralidin suppressed the LPSNigericin-induced production of IL-1β and IL18. Our results indicate that the regulatory effects of psoralidin on inflammasome activation and pyroptosis related cytokine production in RAW 264.7 macrophages are associated with suppression of NLRP3inflammasome activation and inhibition of the release of pyroptosis related cytokines.According to these results, Psoralidine may be considered as a potential therapeutic candidate for the prevention of inflammatory diseases or to support the treatment of inflammation.

 Psoralidin, a prenylated coumestan, has been reported its anti-inflammatory effect, but the regulatory effects on inflammasome activation and pyroptosis-related cytokines are not clear. The aim of this study was to investigate the regulatory role of psoralidin on inflammasome activation and expression of pyroptosis-related cytokines in Lipopolysaccharide LPSNigericin-stimulated RAW 264.7 macrophages. Regulatory mechanism of psoralidin on inflammasome activation was evaluated using Western blotting for NLRP3, adaptor protein apoptosis-associated speckle-like protein ASCand Caspase-1. Pyroptosis-related cytokines were evaluated using RT-PCR for interleukin-1β IL-1βand interleukin-18 IL18.Non-cytotoxic concentration of Psoralidin 5.0µM significantly inhibited LPSNigericin induced inflamasome activation. In addition, pretreatment with psoralidin suppressed the LPSNigericin-induced production of IL-1β and IL18. Our results indicate that the regulatory effects of psoralidin on inflammasome activation and pyroptosis related cytokine production in RAW 264.7 macrophages are associated with suppression of NLRP3inflammasome activation and inhibition of the release of pyroptosis related cytokines.According to these results, Psoralidine may be considered as a potential therapeutic candidate for the prevention of inflammatory diseases or to support the treatment of inflammation.

 Prenile edilmiş bir komestan olan psoralidinin anti-inflamatuvar etkisi bildirilmiştir, ancak inflamazom aktivasyonu ve piroptozis ile ilişkili sitokinler üzerindeki düzenleyici etkileri açık değildir. Bu çalışmanın amacı, psoralidinin Lipopolisakkarit LPSNigerisinile uyarılan RAW 264.7 makrofajlarında inflamazom aktivasyonu ve piroptozis ile ilişkili sitokinlerin ifadelenmesi üzerindeki düzenleyici rolünü araştırmaktı. Psoralidinin inflamazom aktivasyonu üzerindeki düzenleyici mekanizması, NOD Nükleotid bağlama ve oligomerizasyon alanı benzeri reseptör proteini 3 NLRP3, adaptör protein apoptozla ilişkili benek benzeri protein ASC ve Kaspaz-1 için Western blot kullanılarak değerlendirildi. Piroptozis ile ilişkili sitokinler, interlökin-1βIL-1βve interlökin-18 IL-18 için RT-PCR kullanılarak değerlendirildi. Psoralidinin sitotoksik olmayan konsantrasyonu 5.0μM LPS-Nigerisin ile uyarılan inflamazom aktivasyonunu önemli ölçüde inhibe etti. Ek olarak, psoralidin ile ön tedavi, LPSNigerisin kaynaklı IL-1β ve IL18 üretimini bastırdı. Sonuçlarımız, Psoralidinin RAW 264.7 makrofajlarında inflamazom aktivasyonu ve piroptozis ile ilişkili sitokin üretimi üzerindeki düzenleyici etkilerinin, NLRP3 inflamazom aktivasyonunun baskılanması ve piroptoz ile ilgili sitokinlerin salınımının inhibisyonu ile ilişkili olduğunu göstermektedir. Bu sonuçlara göre, Psoralidin, inflamatuvar hastalıkların önlenmesi veya inflamasyon tedavisinin desteklenmesi için potansiyel bir terapötik aday olarak düşünülebilir.

Makale detayları

NLRP3 INFLAMMASOME ACTIVATION IN MACROPHAGE (RAW 264.7) CELLS BY LIPOPOLISACCARIDE/NIGERICIN: REGULATORY EFFECT OF PSORALIDIN

Yazarlar:

Damla Setenci | Merve Nur Sultan Yıldırım | Ahmet Cumaoğlu

Yayıncı:

Erciyes University

Ana Başlıklar:

Eczacılık ve İlaç Bilimleri

Dergi:

Sağlık Bilimleri Dergisi Vol.32 Issue 3, pp.346-350

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001303654

pISSN:

1018-3655

Inflammasomes

Lipopolysaccharides

Pyroptosis

CytokinesInflamazomlar

Lipopolisakkaritler

Piroptozis

Sitokinler

Sayı

Makale detayları

Yazarlar: Damla Setenci | Merve Nur Sultan Yıldırım | Ahmet Cumaoğlu

Yayıncı: Erciyes University

Ana Başlıklar: Eczacılık ve İlaç Bilimleri

Dergi: Sağlık Bilimleri Dergisi Vol.32 Issue 3, pp.346-350

Belge Tipi: Makale

Yayın Tarihi: 4/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001303654

pISSN: 1018-3655

Sayı

Yazarlar:

Damla Setenci | Merve Nur Sultan Yıldırım | Ahmet Cumaoğlu

Yayıncı:

Erciyes University

Ana Başlıklar:

Eczacılık ve İlaç Bilimleri

Dergi:

Sağlık Bilimleri Dergisi Vol.32 Issue 3, pp.346-350

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001303654

pISSN:

1018-3655